INTRODUCTION: The exposures to hazardous antineoplastic drugs (AD) represent serious risks for health care personnel but the exposure limits are not commonly established because of the no-threshold effects (genotoxic action, carcinogenicity) of many ADs. In this study, we discussed and derived practically applicable technical guidance values (TGV) suitable for management of AD risks. METHODS: The long-term monitoring of surface contamination by eight ADs was performed in pharmacies and hospitals in the Czech Republic and Slovak Republic in 2008-2021; in total 2,223 unique samples were collected repeatedly in 48 facilities. AD contamination was studied by LC-MS/MS for cyclophosphamide, ifosfamide, methotrexate, irinotecan, paclitaxel, 5-fluorouracil and gemcitabine and by ICP-MS for total Pt as a marker of platinum-based ADs. RESULTS: The study highlighted importance of exposure biomarkers like 5-fluorouracil and especially carcinogenic and persistent cyclophosphamide, which should be by default included in monitoring along with other ADs. Highly contaminated spots like interiors of laminar biological safety cabinets represent a specific issue, where monitoring of contamination does not bring much added value, and prevention of staff and separated cleaning procedures should be priority. Rooms and surfaces in health care facilities that should be virtually free of ADs (e.g., offices, kitchenettes, daily rooms) were contaminated with lower frequency and concentrations but any contamination in these areas should be carefully examined. DISCUSSION AND CONCLUSIONS: For all other working places, i.e., majority of areas in pharmacies and hospitals, where ADs are being prepared, packaged, stored, transported, or administered to patients, the study proposes a generic TGV of 100 pg/cm2. The analysis of long-term monitoring data of multiple ADs showed that the exceedance of one TGV can serve as an indicator and trigger for improvement of working practices contributing thus to minimizing of unintended exposures and creating a safe work environment.

Masaryk Memorial Cancer Institute Brno Czechia

RECETOX Faculty of Science Masaryk University Brno Czechia

Zobrazit více v PubMed

Kümmerer K, Haiß A, Schuster A, Hein A, Ebert I. Antineoplastic compounds in the environment—substances of special concern. EnvironSci Pollut Res. (2016) 23:14791–14804. 10.1007/s11356-014-3902-8 PubMed DOI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . and Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. 10.3322/caac.21660 PubMed DOI

Alexander M, Connor TH, Bauters T, Alexander MC, Mackenzie BA, Vandenbroucke J, et al. . ISOPP standards for the safe handling of cytotoxics. J Oncol Pharm Pract. (2022) 28:S1–S126. 10.1177/10781552211070933 PubMed DOI

Cherrie JW, Hutchings S, Gorman Ng M, Mistry R, Corden C, Lamb J, et al. . Prioritising action on occupational carcinogens in Europe: a socioeconomic and health impact assessment. Br J Cancer. (2017) 117:274–81. 10.1038/bjc.2017.161 PubMed DOI PMC

Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. (1993) 16:288–95. 10.1097/00002820-199308000-00005 PubMed DOI

Krstev S, Perunicic B, Vidakovic A. Work practice and some adverse health effects in nurses handling antineoplastic drugs. Med Lav. (2003) 94:432–9. PubMed

Hon CY, Chua PPS, Danyluk Q, Astrakianakis G. Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study. J Oncol Pharm Pract. (2014) 20:210–216. 10.1177/1078155213497070 PubMed DOI

Decree 84/2008 Coll . Vyhlaska o spravne lekarenske praxi, blizsích podminkach zachazeni s lecivy v lekarnach, zdravotnickych zarizenich a u dalsich provozovatelu a zarizeni vydavajicich lecive pripravky. Vyhlaska c. 84/2008 Sb. [in Czech] [Good pharmaceutical practice drugs handling conditions for pharmacies, healthcare facilities other entities emitting pharmaceutical products to final consumers; Decree 84/2008 Coll.] (2008). Available online at: https://www.psp.cz/sqw/sbirka.sqw?cz=84&r=2008

Bláhová L, Kuta J, DoleŽalová L, Kozáková Š, Hojdarová T, Bláha L, et al. . Levels and risks of antineoplastic drugs in households of oncology patients, hospices and retirement homes. Environ Sci Eur. (2021) 33:1–14. 10.1186/s12302-021-00544-5 DOI

Doležalová L, Bláhová L, Kuta J, Hojdarová T, Kozáková Š, Bláha L, et al. . Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies. Environ Sci Pollut Res. (2022) 29:26810–9. 10.1007/s11356-021-17607-y PubMed DOI

NIOSH . Managing Hazardous Drug Exposures: Information for Healthcare Settings. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2023–130. (2023).

Mathias PI, MacKenzie BA, Toennis CA, Connor TH. Survey of guidelines and current practices for safe handling of antineoplastic and other hazardous drugs used in 24 countries. J Oncol Pharm Pract. (2019) 25:148–62. 10.1177/1078155217726160 PubMed DOI PMC

Fransman W, Huizer D, Tuerk J, Kromhout H. Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility. Int Arch Occup Environ Health. (2007) 80:396–403. 10.1007/s00420-006-0148-x PubMed DOI

Santos AN, Oliveira RJ, Pessatto LR, Gomes R, Freitas CAF. Biomonitoring of pharmacists and nurses at occupational risk from handling antineoplastic agents. Int J Pharm Pract. (2020) 28:506–511. 10.1111/ijpp.12590 PubMed DOI

Turci R, Sottani C, Spagnoli G, Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B. (2003) 789:169–209. 10.1016/S1570-0232(03)00100-4 PubMed DOI

Villa A, Tremolet K, Martinez B, Petit M, Dascon X, Stanek J, et al. . Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive uhplc-ms/ms method in mrm3 mode. SSRN Electron J. (2022) 1209:1–8. 10.1016/j.jchromb.2022.123411 PubMed DOI

Villa A, Molimard M, Sakr D, Lassalle R, Bignon E, Martinez B, et al. . Nurses' internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study. Int Arch Occup Environ Health. (2021) 94:1839–50. 10.1007/s00420-021-01706-x PubMed DOI

Yuki M, Sekine S, Takase K, Ishida T, Sessink PJM. Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract. (2013) 19:208–17. 10.1177/1078155212459667 PubMed DOI

Chabut C, Tanguay C, Gagné S, Caron N, Bussières JF. Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program. J. Oncol. Pharm. Pract. (2021) 28:343–352. 10.1177/1078155221992103 PubMed DOI

Connor TH, Zock MD, Snow AH. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations. J Occup Environ Hyg. (2016) 13:658–67. 10.1080/15459624.2016.1165912 PubMed DOI PMC

Odraska P, Dolezalova Pharm D, Kuta L, Oravec J, Piler M, Synek Pharm P, et al. . Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies. Arch Environ Occup Health. (2014) 693:148–58. 10.1080/19338244.2013.763757 PubMed DOI

Palamini M, Gagné S, Caron N, Bussières JF. Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results. J. Oncol. Pharm. Pract. (2020) 26:1921–1930. 10.1177/1078155220907125 PubMed DOI

Sottani C, Grignani E, Cornacchia M, Negri S, Saverio F, Cottica D, et al. . Occupational exposure assessment to antineoplastic drugs in nine italian hospital centers over a 5-year survey program. Int J Environ Res Public Health. (2022) 19:8601–18. 10.3390/ijerph19148601 PubMed DOI PMC

Jeronimo M, Colombo M, Astrakianakis G, Hon CY. A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal Bioanal Chem. (2015) 407:7083–92. 10.1007/s00216-015-8868-y PubMed DOI

Kopp B, Schierl R, Nowak D. Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. Int Arch Occup Environ Health. (2013) 86:47–55. 10.1007/s00420-012-0742-z PubMed DOI

Astrakianakis G, Jeronimo M, Griffiths A, Colombo M, Kramer D, Demers PA, et al. . The application of novel field measurement and field evaluation protocols for assessing health care workers' exposure risk to antineoplastic drugs. J Occup Environ Hyg. (2020) 17:373–82. 10.1080/15459624.2020.1777296 PubMed DOI

Schierl R, Böhlandt A, Nowak D. Guidance values for surface monitoring of antineoplastic drugs in german pharmacies. Ann Occup Hyg. (2009) 53:703–11. 10.1093/annhyg/mep050 PubMed DOI

Blahova L, Dolezalova L., Kuta J., Kozáková Š., Bláha L. (2020). Hospitals and Pharmacies as Sources of Contamination by Cytostatic Pharmaceuticals: Long-Term Monitoring in the Czech Republic, in:Heath, E., Isidori, M., Kosjek, T., Filipič M. (,Eds.), Fate and Effects of Anticancer Drugs in the Environment. Springer Nature Switzerland AG, pp. 57–70. 10.1007/978-3-030-21048-9_3 DOI

Chauchat L, Tanguay C, Caron N, Gagné S, Labrèche F, Bussières J, et al. . Surface contamination with ten antineoplastic drugs in 83 Canadian centers. J Oncol Pharm Pract. (2019) 25:1089–1098. 10.1177/1078155218773862 PubMed DOI

Fleury-Souverain S, Mattiuzzo M, Mehl F, Nussbaumer S, Bouchoud L, Falaschi L, et al. . Evaluation of chemical contamination of surfaces during the preparation of chemotherapies in 24 hospital pharmacies. Eur J Hosp Pharm. (2015) 22:333–41. 10.1136/ejhpharm-2014-000549 DOI

Kiffmeyer TK, Tuerk J, Hahn M, Stuetzer H, Hadtstein C, Heinemann A, et al. . Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies-the MEWIP project. Ann Occup Hyg. (2013) 57:444–55. 10.1093/annhyg/mes081 PubMed DOI

Korczowska E, Crul M, Tuerk J, Meier K. Environmental contamination with cytotoxic drugs in 15 hospitals from 11 European countries—results of the MASHA project. Eur J Oncol Pharm. (2020) 3:e24. 10.1097/OP9.0000000000000024 DOI

Roland C, Caron N, Bussières JF. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 canadian hospitals: a 2016 follow-up study. J Occup Environ Hyg. (2017) 14:650–8. 10.1080/15459624.2017.1316389 PubMed DOI

Sottani C, Grignani E, Oddone E, Dezza B, Negri S, Villani S, et al. . Monitoring surface contamination by antineoplastic drugs in Italian hospitals: Performance-based hygienic guidance values (HGVs) Project. Ann Work Expo Heal. (2017) 61:1–9. 10.1093/annweh/wxx065 PubMed DOI

Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, Anzion R, et al. . Erratum: Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 44. (2000) 551–60. 10.1016/S0003-4878(00)00050-8 PubMed DOI

Power LA, Coyne JW, Hawkins B. ASHP guidelines on handling hazardous drugs. Am J Heal Pharm. (2018) 75:1996–2031. 10.2146/ajhp180564 PubMed DOI

Hedmer M, Wohlfart G. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. J Environ Monit. (2012) 14:1968–75. 10.1039/c2em10704j PubMed DOI

Labrèche F, Ouellet C, Roberge B, Caron NJ, Yennek A, Bussières JF, et al. . Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel? Int Arch Occup Environ Health. (2021) 94:1877–88. 10.1007/s00420-021-01731-w PubMed DOI

Sessink PJ. Environmental contamination with cytostatic drugs: past, present and future. Saf Considerations Oncol Pharm Special Ed. (2011) 12:3–5.

Crul M, Simons-Sanders K. Carry-over of antineoplastic drug contamination in Dutch hospital pharmacies. J Oncol Pharm Pract. (2018) 24:483–9. 10.1177/1078155217704990 PubMed DOI

Bláhová L, Kuta J, Doležalová L, Kozáková Š, Krovová T, Bláha L, et al. . The efficiency of antineoplastic drug contamination removal by widely used disinfectants–laboratory and hospital studies. Int Arch Occup Environ Health. (2021) 24:5. 10.1007/s00420-021-01671-5 PubMed DOI

European Commission Directorate-General for Employment Social Affairs Inclusion Sand. Jespersen M, Lassen C, Madsen P. Study Supporting the Assessment of Different Options Concerning the Protection of Workers from Exposure to Hazardous Medicinal Products, including Cytotoxic Medicinal Products - Final Report, Publications Office (2021). Available online at: https://data.europa.eu/doi/10.2767/17127 DOI

Jeronimo M, Arnold S, Astrakianakis G, Lyden G, Stewart Q, Petersen A, et al. . Spatial and temporal variability in antineoplastic drug surface contamination in cancer care centers in Alberta and Minnesota. Ann Work Expo Heal. (2021) 65:760–74. 10.1093/annweh/wxab013 PubMed DOI

Acramel A, Foquet J, Blondeel-Gomes S, Huguet S, Rezai K, Madar O, et al. . Application of an environmental monitoring to assess the practices and control the risk of occupational exposure to cyclophosphamide in two sites of a french comprehensive cancer center. Annal Work Exp Health. (2021) 2:wxac035. 10.1093/annweh/wxac035 PubMed DOI

Dugheri S, Mucci N, Bucaletti E, Squillaci D, Cappelli G, Trevisani L, et al. . Monitoring of surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs). Med. Pr. (2022) 73:383–96. 10.13075/mp.5893.01288 PubMed DOI

Adé A, Chauchat L, Frève JFO, Gagné S, Caron N, Bussières JF, et al. . Comparison of decontamination efficacy of cleaning solutions on a biological safety cabinet workbench contaminated by cyclophos- phamide. Can J Hosp Pharm. (2017) 70:407–14. 10.4212/cjhp.v70i6.1708 PubMed DOI PMC

Simon N, Odou P, Decaudin B, Bonnabry P, Fleury-Souverain S. Efficiency of degradation or desorption methods in antineoplastic drug decontamination: a critical review. J Oncol Pharm Pract. (2019) 25:929–46. 10.1177/1078155219831427 PubMed DOI

Pardhan A, Vu K, Gallo-Hershberg D, Forbes L, Gavura S, Kukreti V, et al. . Evolving best practice for take-home cancer drugs. JCO Oncol Prac. (2021)17:4. 10.1200/OP.20.00448 PubMed DOI